JP2004506438A5 - - Google Patents

Download PDF

Info

Publication number
JP2004506438A5
JP2004506438A5 JP2002520848A JP2002520848A JP2004506438A5 JP 2004506438 A5 JP2004506438 A5 JP 2004506438A5 JP 2002520848 A JP2002520848 A JP 2002520848A JP 2002520848 A JP2002520848 A JP 2002520848A JP 2004506438 A5 JP2004506438 A5 JP 2004506438A5
Authority
JP
Japan
Prior art keywords
hmgcb
cells
class
formulation
mannose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002520848A
Other languages
English (en)
Japanese (ja)
Other versions
JP5008245B2 (ja
JP2004506438A (ja
Filing date
Publication date
Priority claimed from US09/641,471 external-priority patent/US7138262B1/en
Application filed filed Critical
Publication of JP2004506438A publication Critical patent/JP2004506438A/ja
Publication of JP2004506438A5 publication Critical patent/JP2004506438A5/ja
Application granted granted Critical
Publication of JP5008245B2 publication Critical patent/JP5008245B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002520848A 2000-08-18 2001-08-17 高マンノースタンパク質および高マンノースタンパク質の製造方法 Expired - Lifetime JP5008245B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/641,471 US7138262B1 (en) 2000-08-18 2000-08-18 High mannose proteins and methods of making high mannose proteins
US09/641,471 2000-08-18
PCT/US2001/025882 WO2002015927A1 (en) 2000-08-18 2001-08-17 High mannose proteins and methods of making high mannose proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011173243A Division JP5683407B2 (ja) 2000-08-18 2011-08-08 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2011173242A Division JP5840890B2 (ja) 2000-08-18 2011-08-08 高マンノースタンパク質および高マンノースタンパク質の製造方法

Publications (3)

Publication Number Publication Date
JP2004506438A JP2004506438A (ja) 2004-03-04
JP2004506438A5 true JP2004506438A5 (cg-RX-API-DMAC7.html) 2008-10-09
JP5008245B2 JP5008245B2 (ja) 2012-08-22

Family

ID=24572532

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2002520848A Expired - Lifetime JP5008245B2 (ja) 2000-08-18 2001-08-17 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2011173243A Expired - Fee Related JP5683407B2 (ja) 2000-08-18 2011-08-08 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2011173242A Expired - Fee Related JP5840890B2 (ja) 2000-08-18 2011-08-08 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2014209206A Pending JP2015015964A (ja) 2000-08-18 2014-10-10 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2016089304A Expired - Lifetime JP6659443B2 (ja) 2000-08-18 2016-04-27 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2018000449A Expired - Lifetime JP6626133B2 (ja) 2000-08-18 2018-01-05 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2018090467A Expired - Lifetime JP6681428B2 (ja) 2000-08-18 2018-05-09 高マンノースタンパク質および高マンノースタンパク質の製造方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2011173243A Expired - Fee Related JP5683407B2 (ja) 2000-08-18 2011-08-08 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2011173242A Expired - Fee Related JP5840890B2 (ja) 2000-08-18 2011-08-08 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2014209206A Pending JP2015015964A (ja) 2000-08-18 2014-10-10 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2016089304A Expired - Lifetime JP6659443B2 (ja) 2000-08-18 2016-04-27 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2018000449A Expired - Lifetime JP6626133B2 (ja) 2000-08-18 2018-01-05 高マンノースタンパク質および高マンノースタンパク質の製造方法
JP2018090467A Expired - Lifetime JP6681428B2 (ja) 2000-08-18 2018-05-09 高マンノースタンパク質および高マンノースタンパク質の製造方法

Country Status (11)

Country Link
US (2) US7138262B1 (cg-RX-API-DMAC7.html)
EP (3) EP1309340B1 (cg-RX-API-DMAC7.html)
JP (7) JP5008245B2 (cg-RX-API-DMAC7.html)
CN (4) CN102559633A (cg-RX-API-DMAC7.html)
AU (1) AU785460B2 (cg-RX-API-DMAC7.html)
CA (3) CA2388041C (cg-RX-API-DMAC7.html)
HK (1) HK1205183A1 (cg-RX-API-DMAC7.html)
IL (2) IL149029A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02003894A (cg-RX-API-DMAC7.html)
NZ (2) NZ537128A (cg-RX-API-DMAC7.html)
WO (1) WO2002015927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US20050137223A1 (en) * 2003-11-12 2005-06-23 Amicus Therapeutics, Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
EP1866071A4 (en) * 2005-03-03 2013-04-24 Univ Indiana Res & Tech Corp PERMETHYLATION OF OLIGOSACCHARIDES
CA2601797A1 (en) * 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
WO2006110277A1 (en) 2005-04-11 2006-10-19 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
US8202523B2 (en) 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
DK1945665T3 (da) * 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet
ES2391657T3 (es) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
EP2102335B1 (en) * 2007-01-04 2012-02-22 Crucell Holland B.V. Purification of factor xi
ES2660667T3 (es) 2007-05-07 2018-03-23 Protalix Ltd. Biorreactor desechable a gran escala
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
CA2773133A1 (en) 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
CA2790786C (en) * 2010-02-24 2019-09-24 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
SG10201605874TA (en) 2011-04-22 2016-09-29 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
WO2013055888A2 (en) 2011-10-12 2013-04-18 Synageva Biopharma Corp. Recombinant human naglu protein and uses thereof
EP2606741B1 (en) * 2011-12-23 2014-04-16 Foodip Sarl Glycoprotein enriched composition as a food and feed additive and/or as a therapeutic agent
WO2013130963A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
CN102827212B (zh) * 2012-07-25 2015-04-15 中国科学院海洋研究所 一种乙酰化壳三糖的制备方法
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
SI3063287T1 (sl) * 2013-10-31 2025-06-30 Amgen, Inc. Uporaba monenzina za regulacijo glikozilacije rekombinantnih proteinov
AU2015323966A1 (en) 2014-09-29 2017-03-16 Alexion Pharmaceuticals, Inc. Methods of treating mucopolysaccharidosis IIIB (MPSIIIB)
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
CN108795871B (zh) * 2017-04-28 2021-12-03 江南大学 用于生产糖蛋白的动物细胞株及方法、糖蛋白及其用途
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
CN108179160B (zh) * 2018-01-29 2021-05-11 江南大学 一种植烷醇连接的高甘露糖型寡糖的制备方法
CN108588127A (zh) * 2018-04-11 2018-09-28 上海药明生物技术有限公司 一种表达高甘露糖糖型的葡萄糖脑苷脂酶的细胞株及其制备方法和应用
CN113795575A (zh) * 2019-02-04 2021-12-14 自由行疗法有限公司 多核苷酸
CN119530200A (zh) * 2024-11-28 2025-02-28 北海康成(苏州)生物制药有限公司 一种维拉苷酶β的纯化方法和药液

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5272066A (en) 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
WO1989005850A1 (en) * 1987-12-23 1989-06-29 The United States Of America, As Represented By Th Cloned dna for synthesizing unique glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
JPH03503721A (ja) 1988-12-23 1991-08-22 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
JP2893481B2 (ja) 1988-12-23 1999-05-24 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
EP0568647B1 (en) 1991-01-21 1996-09-11 Genzyme Corporation Production of enzymatically active glucocerebrosidase from recombinant cells
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
CA2150956A1 (en) 1992-12-10 1994-06-23 Robert G. L. Shorr Glycolipid enzyme-polymer conjugates
WO1994014837A1 (en) 1992-12-21 1994-07-07 Enzon, Inc. Purification of proteinaceous material
JP3002113B2 (ja) 1994-03-30 2000-01-24 寳酒造株式会社 糖質又は複合糖質の製造方法
EP0675204B1 (en) 1994-03-30 2001-05-30 Takara Shuzo Co. Ltd. Transglycosylating process for producing carbohydrates or glycoconjugates
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
EP0865499B1 (en) * 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
WO1997032591A1 (en) 1996-03-05 1997-09-12 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
NZ506214A (en) * 1996-09-13 2002-11-26 Transkaryotic Therapies Inc Therapy for alpha-galactosidase A deficiency
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JPH10273500A (ja) 1997-03-03 1998-10-13 Noguchi Inst 複合糖ペプチド及びその製造法
JPH10306099A (ja) 1997-03-04 1998-11-17 Noguchi Inst 新規複合糖ペプチドおよびその製法
TW542721B (en) 1997-08-06 2003-07-21 Melaleuca Inc Dietary supplements containing natural ingredients
DE69825288D1 (de) 1997-08-07 2004-09-02 Univ Utah Prodrugs und konjugate von selenolenthaltenden verbindungen und ihre verwendung
US5939279A (en) * 1997-09-18 1999-08-17 The Board Of Trustees Of The University Of Arkansas Inhibition of bacterial binding by high-mannose oligosaccharides
EP1041996A4 (en) 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
GB9802249D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
GB9807464D0 (en) 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
EP0976838A1 (en) 1998-05-06 2000-02-02 Rhone-Poulenc Nutrition Animale Enzymes mixture
JPH11318441A (ja) 1998-05-14 1999-11-24 Nagase & Co Ltd 超耐熱耐酸性アミロプルラナーゼ
KR19990086271A (ko) 1998-05-27 1999-12-15 손경식 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
KR20010052499A (ko) 1998-06-05 2001-06-25 아방티 파르마 소시에테 아노님 베타-시크리타제형 활성을 지닌 폴리펩타이드
PT1137789E (pt) * 1998-12-09 2010-10-21 Phyton Holdings Llc Um método para produzir glicoproteínas possuindo glicosilação de tipo humano
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
EP1189599A2 (en) 1999-06-11 2002-03-27 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖n−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
IL150314A0 (en) 1999-12-30 2002-12-01 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
CN1156702C (zh) 2001-07-11 2004-07-07 上海晶泰生物技术有限公司 采用标记链霉亲和素-生物素技术的蛋白质芯片
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
JP5589165B2 (ja) 2003-01-31 2014-09-17 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー タンパク質欠損性障害の治療のための併用療法
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
ES2391657T3 (es) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
ES2366059T3 (es) 2006-03-17 2011-10-14 Biomarin Pharmaceutical Inc. Ensayos para la detección de anticuerpos anti-enzimas lisosómicas.
NZ572226A (en) 2006-04-18 2011-05-27 Ekr Therapeutics Inc Pre-mixed, ready-to-use IV bolus compositions comprising nicardipine and methods of use
DK2040548T3 (da) 2006-06-23 2012-08-13 Amicus Therapeutics Inc Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US20130017169A1 (en) 2010-03-02 2013-01-17 Protalix Ltd. Multimeric forms of therapeutic proteins and uses thereof
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof

Similar Documents

Publication Publication Date Title
CA2388041A1 (en) High mannose proteins and methods of making high mannose proteins
Schwarz et al. Inhibitors of trimming: new tools in glycoprotein research
JP2015015964A5 (cg-RX-API-DMAC7.html)
UA53655C2 (uk) Спосіб лікування ожиріння
KR20000035992A (ko) 폴리디티오카르바메이트 함유 거대분자 및 치료 및 진단을 위한
JPH01254623A (ja) スフインゴ糖脂質代謝の阻害剤を有効成分として含有する癌治療薬
MXPA01010707A (es) Combinacion de inhibidores de sintesis de glucosilceramida y enzima degradante del glucolipido en terapia.
CA2128244A1 (en) Solid Bodies Containing Active Substances and a Structure Consisting of Hydrophilic Macromolecules, Plus a Method of Producing Such Bodies
EP4146284A1 (en) Methods to genetically modify cells for delivery of therapeutic proteins
JP2026505800A (ja) Hsc特異的抗体結合脂質ナノ粒子及びその使用
Bayard et al. Increased stability and antiviral activity of 2′‐O‐phosphoglyceryl derivatives of (2′‐5′) oligo (adenylate) Roles of phosphodiesterases and phosphatases in (2′‐5′) oligo (adenylate) catabolism
CA2386536A1 (en) Methods for treating muscular dystrophy with bone marrow cells
AU2021268253A1 (en) Methods for targeted insertion of exogenous sequences in cellular genomes
KR20080033501A (ko) 증식성 질환 또는 염증의 치료를 위한3,11b-시스-디히드로테트라베나진
FR2553409B1 (fr) Nouveaux benzenesulfonyl-lactames, leur procede de preparation et leur application comme substance active de compositions pharmaceutiques
DE2930604A1 (de) Doppelstrangige ribonucleinsaeure, verfahren zu ihrer herstellung und diese enthaltende interferon-induktoren
JP2668214B2 (ja) Aids治療薬
US6034112A (en) Use of flupirtine the prophylaxis and therapy of diseases associated with an impairment of the hematopoetic cell system
Nanba et al. GMl-gangliosidosis: Abnormalities in biosynthesis and early processing of β-galactosidase in fibroblasts
Siebert et al. Mitochondrial malic enzyme (EC 1.1. 1.40) in human leukocytes: formal genetics and population genetics
NO20013141L (no) Arylalkanoylderivater, fremgangsmåter for fremstilling derav, deres anvendelse og farmasöytiske preparater inneholdende disse
IL131436A0 (en) Compositions for treatment of disorders involving programmed cell death
Kuroda et al. 3-(4-Carbamoylphenyl)-1-methyltriazene 1-oxide
KR102227398B1 (ko) 신규 에르고스텐올 글리코시드 유도체의 관절염 치료소재를 포함하는 조성물
EP1882744A1 (en) Method for producing an interleukin-2 preparation and the thus obtainable preparation